 Passage Bio, Inc. PASG, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system CNS disorders and the Gene Therapy Program GTP at the University of Pennsylvania UPenn today announced the expansion of their collaboration agreement to include an additional five programs and extending Passage Bios period to exercise new programs for an additional three years through 2025. Additionally, Passage Bio will fund discovery research at GTP and will receive exclusive rights, subject to certain limitations, to technologies resulting from the discovery program for Passage Bio products developed with GTP, such as novel capsids, toxicity reduction technologies and delivery and formulation improvements. 